APOE基因型与阿尔茨海默病认知衰退速率异质性的关联
该研究应用反向时间纵向模型分析1102例尸检确诊的阿尔茨海默病(AD)病例,发现APOE ε4携带者CDR-SOB年增长约1.5倍于ε3/ε3携带者,MMSE年下降约1.1倍于ε3/ε3携带者;APOE ε2携带者MMSE年下降约1.2倍慢于ε3/ε3携带者。APOE ε2和ε4等位基因对认知衰退速率有相反影响,且 largely 独立于AD病理及共病病理。
要点
- APOE ε4携带者CDR-SOB年增长2.12分,快于ε3/ε3的1.44分/年。
- APOE ε4携带者MMSE年下降3.45分,快于ε3/ε3的3.03分/年。
- APOE ε2携带者MMSE年下降2.43分,慢于ε3/ε3的3.03分/年。
核心结论
- APOE ε2和ε4等位基因对AD认知衰退速率有相反影响,ε4加速、ε2减缓,且 largely 独立于AD病理及共病病理。
- APOE基因型是AD临床进展异质性的驱动因素之一。
研究设计与样本
- 研究采用反向时间纵向模型分析1102例尸检确诊的AD病例,来自美国国家阿尔茨海默病协调中心神经病理数据库。
- 病例符合中/频繁神经炎性斑块和Braak缠结分期III期或以上,类似于治疗临床试验中的轻中度AD参与者。
主要发现
- APOE ε4携带者CDR-SOB年增长2.12分,约为APOE ε3/ε3携带者1.44分/年的1.5倍,约为APOE ε2携带者1.65分/年的1.3倍。
- APOE ε4携带者MMSE年下降3.45分,约为APOE ε3/ε3携带者3.03分/年的1.1倍,约为APOE ε2携带者2.43分/年的1.4倍。
- APOE ε2携带者MMSE年下降2.43分,约为APOE ε3/ε3携带者3.03分/年的1.2倍慢。
- APOE ε2与APOE ε3/ε3在CDR-SOB增长上的差异无统计学意义。
- 控制AD神经病理变化及共病病理的影响后,上述结果基本不变。
临床怎么用
- 在AD临床试验设计和解读中,应考虑APOE基因型对认知衰退速率的异质性影响。
- APOE ε4携带者认知衰退更快,可能需要更早干预或调整试验样本量。
- APOE ε2携带者认知衰退较慢,可能影响试验终点事件的观察。
局限性
- 研究基于尸检确诊的AD病例,可能不代表所有AD患者。
- 样本来自特定数据库,存在选择偏倚可能。
- 未明确报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the hypothesis that the APOE genotype is a significant driver of heterogeneity in Alzheimer disease (AD) clinical progression, which could have important implications for clinical trial design and interpretation. METHODS: We applied novel reverse-time longitudinal models to analyze the trajectories of Clinical Dementia Rating Sum of Boxes (CDR-SOB) and Mini-Mental State Examination (MMSE) scores-2 common outcome measures in AD clinical trials-in 1,102 autopsy-proven AD cases (moderate/frequent neuritic plaques and Braak tangle stage III or greater) from the National Alzheimer's Coordinating Center Neuropathology database resembling participants with mild to moderate AD in therapeutic clinical trials. RESULTS: APOE ε4 carriers exhibited ≈1.5 times faster CDR-SOB increase than APOE ε3/ε3 carriers (2.12 points per year vs 1.44 points per year) and ≈1.3 times faster increase than APOE ε2 carriers (1.65 points per year), whereas APOE ε2 vs APOE ε3/ε3 difference was not statistically significant. APOE ε4 carriers had ≈1.1 times faster MMSE decline than APOE ε3/ε3 carriers (-3.45 vs -3.03 points per year) and ≈1.4 times faster decline than APOE ε2 carriers (-2.43 points per year), whereas APOE ε2 carriers had ≈1.2 times slower decline than APOE ε3/ε3 carriers (-2.43 vs -3.03 points per year). These findings remained largely unchanged after controlling for the effect of AD neuropathologic changes on the rate of cognitive decline and for the presence and severity of comorbid pathologies. CONCLUSION: Compared to the APOE ε3/ε3 reference genotype, the APOE ε2 and ε4 alleles have opposite (slowing and accelerating, respectively) effects on the rate of cognitive decline, which are clinically relevant and largely independent of the differential APOE allele effects on AD and comorbid pathologies. Thus, APOE genotype contributes to the heterogeneity in rate of clinical progression in AD.
引用
- Qian J, Betensky RA, Hyman BT, et al. Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. Neurology. 2021. PMID: 33771840. doi:10.1212/WNL.0000000000011883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。